Company insight
Evolution of single-use systems for bioprocessing
Qosina is a leading global supplier of more than 5,000 OEM single-use components to the medical and pharmaceutical industries. Its mission is to provide the best customer experience possible by helping its customers find, order and receive quality medical components quickly and accurately.
bioprocessing was born in the early 1990s, with two main players: HyClone Laboratories and Stedim. HyClone, a supplier of serum and cell culture media, began to use ‘bio’ bags for packaging sterile cell culture media. Stedim, on the other hand, was already a supplier of 2D EVA bags for the parenteral nutrition market since the late 1970s. Soon, HyClone’s customers began asking them to supply not only the bags filled with media, but also empty sterile bags for use
S ingle-use
Qosina has expanded its portfolio to serve the requirements of SUS integrators and meet unmet needs in the bioprocess space.
in their own processes. Stedim saw the opportunity to offer different versions of their existing products to the bioprocess industry and in about 1998, the Flexboy bag was born.
Since that time, an entire industry has developed. The strong underlying benefits of single-use components for biopharmaceutical companies has driven double-digit growth rates for more than a decade, attracting more suppliers to enter the single-use market. Today, suppliers range from large multinational total solution providers to smaller entrepreneurs serving just a few local customers.
The bioprocess boom
Single-use systems (SUS) are traditionally custom designed for an individual customer, creating a conflict between the need to be fast and flexible under appropriate GMP controls as the business scales up. The early success led to occasional criticism of SUS as inflexible
and slow, with long lead times. The stage was then set for new players to enter the market and the ‘fast and flexible’ business model was born. The bioprocess boom of 2020, which seems to be continuing unabated into 2021, has attracted even more players into this space, with more and more integrators entering the market. But this market is not easy. End-users demand custom solutions with a quick turnaround, and the fast and flexible business model remains the key to success for many. The needs of these integrators are not well served by the existing sales channels for single-use bioprocessing components. Most component OEMs only sell their own products, and have high minimum order quantities and long lead times. Regional distributors often carry no inventory, have a limited product range and may be shifting away from component distribution to focus on becoming an integrator. The large catalogue houses
Medical Device Developments /
www.nsmedicaldevices.com
tend to have high prices, spotty inventory, gaps in their portfolio, and insufficient quality and regulatory infrastructure. The misalignment of customer needs and sales channel support leads to difficulties for the integrators: their component warehouses are too big and are filled with the wrong inventory. Their picking, kitting and warehousing activities have become overwhelming. They’ve become dependent on too many suppliers, with supplier lead times driving their production schedule, undermining the fast and flexible model.
Serve the needs of SUS integrators This unmet need in the bioprocess space has led Qosina, a leading global supplier to the medical device industry for 40 years, to expand its portfolio to serve the needs of SUS integrators. It has leveraged this experience and its extensive supply chain to provide a much-needed resource for bioprocess.
Qosina enables SUS integrators to focus on being fast and flexible without sacrificing assurance of supply. It does this by leveraging its strengths to the supply of SUS components. It now has a comprehensive portfolio of SUS components, and SUS integrators can outsource their warehousing and kitting activities. In addition, technical, quality and regulatory documentation can be easily downloaded directly from its website. ●
www.qosina.com/bioprocess. 43
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133
